PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: Breast cancer
Advisory Panel Rejects Avastin For Breast Cancer Treatment
An FDA advisory panel on Tuesday voted 12–1 to discontinue Avastin (bevacizumab) as a treatment for advanced breast cancer due to post-market studies stating that the treatment does not to increase patient lifespan by any significant length of time.
This is a huge problem for Roche who purchased the treatment as part of its merger with [...]
Posted in FDA, Safety Also tagged Avastin, Bevacizumab, Cancer, Chemotherapy, Clinical trial, Food and Drug Administration, Genentech, Roche 1 Comment
Judge Spikes Myriad Genetic’s Control of Genes
Image via Wikipedia
Score one for nature. A US district court judge on Monday declared that pharma companies can’t patent individual genes because they are they are not, in fact, creating them.
Last spring, Myriad Genetics was taken to task by the ACLU for monopolizing a patent it had discovered for breast cancer. The civil rights group [...]
Posted in Biotech, News Also tagged American Civil Liberties Union, Gene patent, Intellectual property, Myriad Genetics, Patent, Peter Meldrum, United States district court 1 Comment
Q&A with Steven Paul: Lilly’s New Development Plan
Last week, Lilly announced a major restructuring plan focused around the creation of one Developmental Center of Excellence and several individual business units. The media (Pharm Exec included) focused on the news that 5,500 jobs were being cut as part of the plan. This week, we’re talking to Lilly to find out what the company’s [...]
Posted in Strategy Also tagged Biotechnology and Pharmaceuticals, business, Cancer, Clinical trial, Lilly Research Laboratories, Oncology, Research and development 3 Comments
NICE Stats Spur Controversy and Back Patting
The UK’s National Health Service has released its first statistics that show how NICE approval has affected medicines uptake in the UK. The NHS Information Centre’s Metrics Working Group looked at 26 medicines that the NICE has said should be reimbursed and how they were prescribed in 2008. It then compared the actual usage with [...]
Patients on the Picket Line